93
Participants
Start Date
December 5, 2022
Primary Completion Date
October 29, 2024
Study Completion Date
October 29, 2024
AZD6793
AZD6793 will be administered orally
Placebo
Placebo will be administered orally
Research Site, Harrow
Research Site, Wythenshawe
Lead Sponsor
AstraZeneca
INDUSTRY